Evidence map›Paper›PMID 25848944›Full record

ArticlePloS one2015

A new method for discovering disease-specific MiRNA-target regulatory networks.

Miriam Baglioni, Francesco Russo, Filippo Geraci, Milena Rizzo, Giuseppe Rainaldi, Marco Pellegrini

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Miriam BaglioniInstitute of Informatics and Telematics (IIT), National Research Council (CNR), Via G. Moruzzi 1, 56124, Pisa, Italy.
Francesco RussoLaboratory of Integrative Systems Medicine (LISM), Institute of Informatics and Telematics (IIT) and Institute of Clinical Physiology (IFC), National Research Council (CNR), Via G. Moruzzi 1, 56124, Pisa, Italy; Department of Computer Science, University of Pisa, Largo Bruno Pontecorvo 3, 56127, Pisa, Italy.
Filippo GeraciInstitute of Informatics and Telematics (IIT), National Research Council (CNR), Via G. Moruzzi 1, 56124, Pisa, Italy.
Milena RizzoInstitute of Clinical Physiology (IFC), National Research Council (CNR), Via G. Moruzzi 1, 56124, Pisa, Italy.
Giuseppe RainaldiLaboratory of Integrative Systems Medicine (LISM), Institute of Informatics and Telematics (IIT) and Institute of Clinical Physiology (IFC), National Research Council (CNR), Via G. Moruzzi 1, 56124, Pisa, Italy.
Marco PellegriniLaboratory of Integrative Systems Medicine (LISM), Institute of Informatics and Telematics (IIT) and Institute of Clinical Physiology (IFC), National Research Council (CNR), Via G. Moruzzi 1, 56124, Pisa, Italy.
Istituto di Fisiologia Clinica · ITNational Research Council · ITInstitute of Informatics and Telematics · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genes and their expression regulation are among the key factors in the comprehension of the genesis and development of complex diseases. In this context, microRNAs (miRNAs) are post-transcriptional regulators that play an important role in gene expression since they are frequently deregulated in pathologies like cardiovascular disease and cancer. In vitro validation of miRNA--targets regulation is often too expensive and time consuming to be carried out for every possible alternative. As a result, a tool able to provide some criteria to prioritize trials is becoming a pressing need. Moreover, before planning in vitro experiments, the scientist needs to evaluate the miRNA-target genes interaction network. In this paper we describe the miRable method whose purpose is to identify new potentially relevant genes and their interaction networks associate to a specific pathology. To achieve this goal miRable follows a system biology approach integrating together general-purpose medical knowledge (literature, Protein-Protein Interaction networks, prediction tools) and pathology specific data (gene expression data). A case study on Prostate Cancer has shown that miRable is able to: 1) find new potential miRNA-targets pairs, 2) highlight novel genes potentially involved in a disease but never or little studied before, 3) reconstruct all possible regulatory subnetworks starting from the literature to expand the knowledge on the regulation of miRNA regulatory mechanisms.

Indexed as

Computational BiologyGene Expression ProfilingGene Regulatory NetworksHumansMaleMicroRNAsProstatic NeoplasmsRNA, MessengerMicroRNAsRNA, Messenger

Identifiers

PMID25848944
PMCPMC4388573
OpenAlexW2012706837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.